Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome

Kebapcilar L., Yuksel A., Bozkaya G., Taner C. E., Kebapcilar A. G., Bilgir O., ...Daha Fazla

CENTRAL EUROPEAN JOURNAL OF MEDICINE, cilt.4, sa.4, ss.423-427, 2009 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 4 Sayı: 4
  • Basım Tarihi: 2009
  • Doi Numarası: 10.2478/s11536-009-0074-x
  • Dergi Adı: CENTRAL EUROPEAN JOURNAL OF MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.423-427
  • Anahtar Kelimeler: Ethinylestradiol, Cyproterone acetate, Metformin, ADMA, PCOS, ESTRADIOL-CYPROTERONE ACETATE, HORMONE-REPLACEMENT THERAPY, NITRITE/NITRATE LEVELS, DIMETHYLARGININE, PROGESTINS, ENDOCRINE, SYNTHASE
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

To determine the effects of EE/CA (Ethinylestradiol/Cyproterone Acetate) and EE/CA-metformin treatments on the asymmetric dimethylarginine (ADMA) levels in women with PCOS (Polycystic Ovary Syndrome). Among 43 patients diagnosed with PCOS, one study arm (n=22) was administered (35 mu g EE, 2mg CA) and the other (n=21) was administered (35 mu g EE, 2mg CA plus 1700mg metformin). Serum ADMA, lipid profile, androgens, insulin, and HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) values were assessed prior to treatment and after 3 months of therapy. A significant reduction in ADMA levels relative to pre-treatment in the EE/CA+ metformin group (1.2+/-0.4 vs 0.95+/-0.4, p=0.016) compared to the EE/CA group (1.0+/-0.5 vs 1.03+/-0.4, p >0.05). Andogens, insulin and HOMA-IR levels decreased in both treatment groups. All lipid profiles significantly improved in-group EE/CA+ metformin while no significant decrease was observed in TG and HDL-cholesterol levels in EE/CA group. Post-treatment levels of HDL-C levels correlated significantly with the reducing ADMA levels in the EE/CA+ metformin group (P=0.005, r=0.602). Adding metformin to EE/CA therapy in PCOS may beneficial endothelium effects associated with reduction of ADMA levels.